In advanced breast cancer (ABC), the selective ER degrader (SERD) fulvestrant is licensed for use in the first and second line, both as a single agent, and in combination with targeted therapies, including CDK4/6 inhibitors and alpelisib (1–3). The gene discussed is ESR1; the disease is breast carcinoma.